Bronchopulmonary dysplasia (BPD) is a pulmonary disorder that causes significant morbidity and mortality in premature infants. BPD is pathologically characterized by inflammation, fibrosis, and mucosal necrosis, which leads to emphysematous coalescence of alveoli. We tested the hypothesis that azithromycin, a macrolide antibiotic, would decrease the severity of lung injury in an animal model of BPD.
Sixty-three rat pups were randomly divided equally into control, hyperoxia, and hyperoxia plus azithromycin groups. The hyperoxia groups were exposed to > 95% oxygen from days of life 4 to 14. On day 14, the animals were processed for lung histology and tissue analysis. Lung morphology was assessed by mean linear intercept, a measure of alveolar size, with larger values corresponding to lungs that are more emphysematous. The degree of lung inflammation was assessed by quantifying interleukin-6 (IL-6) from lung homogenate.
Fifty pups survived to day 14 (control = 21, hyperoxia = 11, hyperoxia + azithromycin = 18). Mortality was increased in the hyperoxia group versus the control group (p < .0001). Treatment with azithromycin improved survival in animals subjected to hyperoxia (p < .05). Azithromycin significantly decreased lung damage as determined by the mean linear intercept in the hyperoxia groups (p < .001). Finally, azithromycin-treated pups had lower levels of IL-6 in lung homogenate from the hyperoxia groups (p < .05).
Azithromycin treatment resulted in improved survival, less emphysematous change, and decreased IL-6 levels in an animal model of BPD.
TamaokiJ.The effects of macrolides on inflammatory cells. Chest2004;125(2 Suppl):41S–50S; quiz 51S.
2.
ScaglioneF, RossoniG.Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother1998;41Suppl B:47–50.
3.
CarevicO, DjokicS.Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes. Agents Actions1988;25:124–31.
4.
WalesD, WoodheadM.The anti-inflammatory effects of macrolides. Thorax1999;54Suppl 2:S58–62.
RenW, LiXH, ChenBD, WooleyPH.Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity. J Orthop Res2004;22:21–9.
7.
JaffeA, BushA.Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol2001;31:464–73.
8.
CulicO, ErakovicV, CepelakI, . Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol2002;450:277–89.
9.
TanimotoH.A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot Chemother1991;44:94–8.
10.
WolterJ, SeeneyS, BellS, . Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax2002;57:212–6.
11.
DaviesG, WilsonR.Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax2004;59:540–1.
12.
GerhardtSG, McDyerJF, GirgisRE, . Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med2003;168:121–5.
13.
HoibyN.Diffuse panbronchiolitis and cystic fibrosis: East meets. West Thorax1994;49:531–2.
14.
SakitoO, KadotaJ, KohnoS, . Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration1996;63:42–8.
15.
KobayashiH.Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med1995;99(6A):26S–30S.
16.
KhanTZ, WagenerJS, BostT, . Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med1995;151:1075–82.
17.
GreallyP, HussainMJ, PriceJF, ColemanR.Interleukin-1 alpha and soluble interleukin-2 receptor in atopic dermatitis. Arch Dis Child1992;67:1413.
18.
KonstanMW, ByardPJ, HoppelCL, DavisPB.Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med1995;332:848–54.
19.
EquiA, Balfour-LynnIM, BushA, RosenthalM.Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet2002;360:978–84.
20.
BancalariE.Neonatal-perinatal medicine: diseases of the fetus and infant. 7th ed.Philadelphia, PA: Mosby; 2002.
21.
NorthwayWHJr, MossRB, CarlisleKB, . Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med1990;323:1793–9.
22.
ChoiCW, KimBI, KimHS, . Increase of interleukin-6 in tracheal aspirate at birth: a predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr2006;95:38–43.
23.
MunshiUK, NiuJO, SiddiqMM, PartonLA.Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol1997;24:331–6.
24.
BagchiA, ViscardiRM, TaciakV, . Increased activity of interleukin-6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res1994;36:244–52.
25.
WatterbergKL, DemersLM, ScottSM, MurphyS.Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics1996;97:210–5.
26.
JonssonB, TullusK, BraunerA, . Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal NeonatalEd1997;77:F198–201.
27.
BartonBE.IL-6: insights into novel biological activities. Clin Immunol Immunopathol1997;85:16–20.
28.
PerlmutterDH, MayLT, SehgalPB.Interferon beta 2/interleukin 6 modulates synthesis of alpha 1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest1989;84:138–44.
29.
PerlmutterDH. IFN beta 2/IL-6 is one of several cytokines that modulate acute phase gene expression in human hepatocytes and human macrophages. Ann N Y Acad Sci1989;557332-41; discussion 341–2.
30.
KishimotoT.The biology of interleukin-6. Blood1989;74:1–10.
31.
JirikFR, PodorTJ, HiranoT, . Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol1989;142:144–7.
32.
EliasJA, LentzV.IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger. RNA J Immunol1990;145:161–6.
33.
CrestaniB, CornilletP, DehouxM, . Alveolar type II epithelial cells produce interleukin-6 in vitro and in vivo. Regulation by alveolar macrophage secretory products. J Clin Invest1994;94:731–40.
34.
CrestaniB, SetaN, DeBandt M, . Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med1994;149:1260–5.
35.
WatterbergKL, GerdesJS, ColeCH, . Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics2004;114:1649–57.
36.
YehTF, LinYJ, LinHC, . Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med2004;350:1304–13.
37.
BucherJR, RobertsRJ.The development of the newborn rat lung in hyperoxia: a dose-response study of lung growth, maturation, and changes in antioxidant enzyme activities. Pediatr Res1981;15:999–1008.
38.
MargrafLR, TomashefskiJFJr, BruceMC, DahmsBB.Morphometric analysis of the lung in bronchopulmonary dysplasia. Am Rev Respir Dis1991;143:391–400.
39.
DunnillMS.Quantitative methods in the study of pulmonary pathology. Thorax1962;17:320–8.
40.
TysonJE, WrightLL, OhW, . Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med1999;340:1962–8.
41.
VanMarter LJ.Strategies for preventing bronchopulmonary dysplasia. Curr Opin Pediatr2005;17:174–80.
42.
Ben-AriJ, MakhoulIR, DorioRJ, . Cytokine response during hyperoxia: sequential production of pulmonary tumor necrosis factor and interleukin-6 in neonatal rats. Isr Med Assoc J2000;2:365–9.
43.
WarnerBB, StuartLA, PapesRA, WispeJR.Functional and pathological effects of prolonged hyperoxia in neonatal mice. Am J Physiol1998;275(1 Pt 1):L110–7.
44.
CoalsonJJ.Pathology of new bronchopulmonary dysplasia. Semin Neonatol2003;8:73–81.
45.
JobeAJ.The new BPD: an arrest of lung development. Pediatr Res1999;46:641–3.
46.
KanazawaS, NomuraS, MuramatsuM, . Azithromycin and bronchiolitis obliterans. Am J Respir Crit Care Med2004;169:654–5.
47.
KhairOA, DevaliaJL, AbdelazizMM, . Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J1995;8:1451–7.
48.
KawasakiS, TakizawaH, OhtoshiT, . Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother1998;42:1499–502.
49.
YiM, JankovRP, BelcastroR, . Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. Am J Respir Crit Care Med2004;170:1188–96.
50.
JankovRP, JohnstoneL, LuoX, . Macrophages as a major source of oxygen radicals in the hyperoxic newborn rat lung. Free Radic Biol Med2003;35:200–9.
